Jul 25, 2024, 21:25
Elad Sharon: Another win for patients with ALL
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X:
“Another win for NCI, NCI CTEP Clinical Research, ECOG-ACRIN Cancer Research Group, but especially for patients with ALL! Amazing results with Amgen’s blinatumomab and for immunotherapy! Already approved by FDA Oncology...”
Source: Elad Sharon/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 26, 2024, 18:39
Oct 26, 2024, 18:30
Oct 26, 2024, 18:28
Oct 26, 2024, 18:16
Oct 26, 2024, 18:03